Selected Comments from Survey Participants
i. How do the patients describe the challenges of PCa treatment with
standard ADT agents (i.e., LHRH agonist/antagonist depot injections
and the oral drug, Orgovyx)?
ii. What do the patients envision as the benefits of ADT with LHRH
agonists/antagonists?
iii. How do men view transdermal estradiol (tE2) products as options
for ADT?